AKT1 and leukemia: AKT inhibitor MK2206 synergistically enhanced prednisolone sensitivity in leukemia cells from 8/11 patients, while mTOR inhibitors AZD8055 and everolimus acted synergistically when combined with prednisolone in 10/11 and 8/8 patient samples, respectively, including both steroid-resistant patients.